2019
Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Montanari F, Deng C, Sawas A, Lue J, Marchi E, Radeski D, Cheng B, Bhagat G, O'Connor O. Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype. Blood 2019, 134: 2909. DOI: 10.1182/blood-2019-131841.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderDiffuse large B-cell lymphomaMonomorphic post-transplant lymphoproliferative disorderProgression-free survivalMedian progression-free survivalOverall survivalR-CHOPR-EPOCHGerminal centersCell of originImmunosuppressive therapyEBV infectionLymphoproliferative disordersTerms of PFSBetter progression-free survivalDLBCL subtypesCommon first-line therapySeattle GeneticsDiffuse large B-cell lymphoma (DLBCL) subtypeLarge B-cell lymphomaMonths-24 yearsComplete response rateMedian overall survivalPrimary refractory diseaseFirst-line therapy
2017
Treatment and Prognosis
Montanari F, Diefenbach C. Treatment and Prognosis. Molecular Pathology Library 2017, 197-219. DOI: 10.1007/978-3-319-68094-1_9.Peer-Reviewed Original ResearchHodgkin's lymphomaPositron emission tomographyRisk assessment toolClinical prognostic scoring systemsFirst-line therapyPrognostic scoring systemRisk-adapted approachGoal of treatmentNew treatment strategiesPossibility of cureLong-term toxicityAssessment toolRelapsed patientsPediatric patientsPrognostic factorsPromising immunotherapyStandard treatmentTherapeutic decisionsTreatment strategiesNew therapiesTherapeutic strategiesPatientsScoring systemEmission tomographyTreatment standards
2015
Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F, Diefenbach CS. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy. Clinical Advances In Hematology And Oncology 2015, 13: 518-24. PMID: 26351815.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaCHL microenvironmentAutologous stem cell transplantLong-term disease controlTumor microenvironmentHeterogeneous inflammatory infiltratesReed-Sternberg (HRS) tumor cellsFirst-line therapyStem cell transplantAdvanced-stage patientsNew biologic insightsRelapsed patientsCell transplantInflammatory infiltrateHodgkin's lymphomaClinical trialsTherapeutic strategiesTumor growthTumor cellularityDisease controlNovel antitumor strategyBiologic insightsHRS cellsTumor cellsAntitumor strategy
2014
The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)
Radeski D, Hoehn D, Montanari F, Alobeid B, Zhang Y, Amengual J, Sawas A, Deng C, O’Connor O, Bhagat G. The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood 2014, 124: 4449. DOI: 10.1182/blood.v124.21.4449.4449.Peer-Reviewed Original ResearchMonomorphic post-transplant lymphoproliferative disorderPost-transplant lymphoproliferative disorderProgression-free survivalProlonged progression-free survivalCell of originAdvanced stage diseaseExtra-nodal involvementPrimary refractory diseaseFirst-line therapyR-CHOPR-EPOCHOverall survivalRituximab monotherapyLine therapyNodal involvementRefractory diseaseStage diseaseClinical presentationLymphoproliferative disordersTreatment regimensB cellsBone marrow/stem cell transplantationAutologous stem cell transplantCommon first-line therapyNon-germinal center B-cellRelapsed Hodgkin Lymphoma: Management Strategies
Montanari F, Diefenbach C. Relapsed Hodgkin Lymphoma: Management Strategies. Current Hematologic Malignancy Reports 2014, 9: 284-293. PMID: 24942298, PMCID: PMC4909353, DOI: 10.1007/s11899-014-0220-7.Peer-Reviewed Original ResearchConceptsStem cell transplantAutologous stem cell transplantHigh-dose chemotherapyCell transplantHodgkin's lymphomaAllogeneic hematopoietic stem cell transplantHematopoietic stem cell transplantChemotherapy-refractory diseaseRelapsed Hodgkin lymphomaTransient disease controlElderly patient populationFirst-line therapyManagement of patientsBrentuximab vedotinDose chemotherapyRefractory diseaseComplete responseConventional therapyPatient populationNovel therapiesNew agentsPatientsDisease controlTransplantTherapy
2006
Role of the molecular staging and response in the management of follicular lymphoma patients
Arcaini L, Colombo N, Bernasconi P, Calatroni S, Passamonti F, Orlandi E, Bonfichi M, Burcheri S, Della Porta M, Rumi E, Montanari F, Algarotti A, Pascutto C, Lazzarino M. Role of the molecular staging and response in the management of follicular lymphoma patients. Leukemia & Lymphoma 2006, 47: 1018-1022. PMID: 16840191, DOI: 10.1080/10428190500467834.Peer-Reviewed Original ResearchConceptsBcl-2/IgH rearrangementBcl-2 rearrangementBcl-2-negative patientsBcl-2 positive patientsPeripheral bloodMedian EFSMolecular respondersBone marrowNegative patientsPositive patientsClinical featuresBetter EFSIgH rearrangementsMedian event-free survivalBcl-2 negative casesEvent-free survivalFirst-line therapyCohort of patientsFollicular lymphoma patientsBcl-2Onset of diseaseMolecular responseBcl-2-positive casesInitial stagingLymphoma patients